News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gene Security Network Initiates Clinical Trial for Its PGD Technology in Partnership with Ferring Pharmaceuticals


10/25/2010 11:17:33 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gene Security Network (GSN) announced today that it has initiated enrollment for a prospective randomized trial in collaboration with Ferring Pharmaceuticals to evaluate the impact of GSN’s advanced preimplantation genetic diagnosis (PGD) with Parental Support™ on pregnancy and implantation rates in IVF. “IPSO”, or – “Impact of Parental Support on pregnancy Outcomes”, is a multicenter U.S. trial designed to evaluate the potential of GSN’s PGD technology to increase in vitro fertilization (IVF) success. This study is the first multicenter trial to evaluate the efficacy of next generation microarray PGD.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES